Uncategorized
RIDE, RISE extension study shows stable visual outcomes
NEW ORLEANS — A long-term open-label extension of the RIDE and RISE trials showed sustained gains in visual acuity in patients receiving ranibizumab for diabetic macular edema, according to a poster presented here.“The safety profile of ranibizumab in the open-label extension appeared similar to that observed in the controlled core studies, based on the types of [adverse events] reported,” David S. Boyer, MD, and colleagues reported in the poster at the American Academy of Ophthalmology meeting.The RIDE and RISE trials included 759 patients with DME who received intravitreal injections of (Read more...)